CA3023601A1 - Cd200 mutant and its uses - Google Patents

Cd200 mutant and its uses Download PDF

Info

Publication number
CA3023601A1
CA3023601A1 CA3023601A CA3023601A CA3023601A1 CA 3023601 A1 CA3023601 A1 CA 3023601A1 CA 3023601 A CA3023601 A CA 3023601A CA 3023601 A CA3023601 A CA 3023601A CA 3023601 A1 CA3023601 A1 CA 3023601A1
Authority
CA
Canada
Prior art keywords
protein
seq
wild
mutated
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3023601A
Other languages
English (en)
French (fr)
Inventor
Philip Huxley
Joseph SHERIDAN
Jonathan HEAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ducentis Biotherapeutics Ltd
Original Assignee
Ducentis Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ducentis Biotherapeutics Ltd filed Critical Ducentis Biotherapeutics Ltd
Publication of CA3023601A1 publication Critical patent/CA3023601A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3023601A 2016-05-10 2017-05-10 Cd200 mutant and its uses Pending CA3023601A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1608197.8A GB201608197D0 (en) 2016-05-10 2016-05-10 Novel proteins
GB1608197.8 2016-05-10
PCT/GB2017/051303 WO2017194941A1 (en) 2016-05-10 2017-05-10 Cd200 mutant and its uses

Publications (1)

Publication Number Publication Date
CA3023601A1 true CA3023601A1 (en) 2017-11-16

Family

ID=56297468

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3023601A Pending CA3023601A1 (en) 2016-05-10 2017-05-10 Cd200 mutant and its uses

Country Status (15)

Country Link
US (1) US11203628B2 (https=)
EP (1) EP3455247A1 (https=)
JP (1) JP6997767B2 (https=)
KR (2) KR102498901B1 (https=)
CN (1) CN109219614B (https=)
AU (1) AU2017264825B2 (https=)
BR (1) BR112018073280A2 (https=)
CA (1) CA3023601A1 (https=)
EA (1) EA201892554A1 (https=)
GB (1) GB201608197D0 (https=)
IL (1) IL262846B2 (https=)
MX (1) MX386295B (https=)
SG (1) SG11201809677XA (https=)
WO (1) WO2017194941A1 (https=)
ZA (1) ZA201807079B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
KR102186780B1 (ko) 2019-02-18 2020-12-04 박주현 비행부와 탑승부를 분리하여 축으로 결합한 유인드론
CN110859951A (zh) * 2019-09-23 2020-03-06 中国药科大学 Cd200蛋白和cd200融合蛋白在制备治疗银屑病药物中的应用
GB202115803D0 (en) * 2021-11-03 2021-12-15 Ducentis Biotherapeutics Ltd Novel proteins
AU2023265174A1 (en) * 2022-05-06 2024-12-12 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins
CN119365483A (zh) * 2022-05-06 2025-01-24 杜森蒂斯生物治疗有限公司 新型cd200融合蛋白
GB2626300A (en) * 2022-12-08 2024-07-24 Ducentis Biotherapeutics Ltd Mutated CD200 proteins and methods of use therof
GB202303291D0 (en) 2023-03-07 2023-04-19 Secr Defence Medicament and medicament combination for use in the treatment of infectious disease
GB202306711D0 (en) * 2023-05-05 2023-06-21 Ducentis Biotherapeutics Ltd Novel proteins
WO2025106841A1 (en) * 2023-11-15 2025-05-22 The University Of Chicago Methods and compositions for inducing antigen specific tolerance

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
EP1032662B1 (en) * 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Methods and compositions for immunomodulation
MXPA01010480A (es) * 1999-04-13 2002-03-27 Schering Corp Usos novedosos de la proteina 0x2 de mamifero y reactivos relacionados.
EP1261743A2 (en) * 2000-03-07 2002-12-04 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2429579A1 (en) * 2000-11-22 2002-05-30 Trillium Therapeutics Inc. Truncated cd200
KR20130108481A (ko) * 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2008206502A1 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts
CN102448982B (zh) * 2009-03-31 2018-04-20 华盛顿大学 用于调节靶细胞上补体调节蛋白的活性的组合物和方法
CA2786692A1 (en) * 2010-01-11 2011-07-14 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Also Published As

Publication number Publication date
US11203628B2 (en) 2021-12-21
BR112018073280A2 (pt) 2019-03-19
EA201892554A1 (ru) 2019-04-30
US20190367580A1 (en) 2019-12-05
GB201608197D0 (en) 2016-06-22
IL262846A (en) 2018-12-31
KR20230025937A (ko) 2023-02-23
IL262846B2 (en) 2023-02-01
KR102689460B1 (ko) 2024-07-26
NZ747665A (en) 2025-10-31
JP6997767B2 (ja) 2022-03-04
IL262846B (en) 2022-10-01
EP3455247A1 (en) 2019-03-20
KR102498901B1 (ko) 2023-02-10
AU2017264825A1 (en) 2018-11-15
SG11201809677XA (en) 2018-11-29
KR20190003761A (ko) 2019-01-09
CN109219614B (zh) 2022-05-24
AU2017264825B2 (en) 2021-04-08
CN109219614A (zh) 2019-01-15
ZA201807079B (en) 2019-07-31
MX2018013778A (es) 2019-08-01
WO2017194941A1 (en) 2017-11-16
JP2019518788A (ja) 2019-07-04
MX386295B (es) 2025-03-18

Similar Documents

Publication Publication Date Title
AU2017264825B2 (en) CD200 mutant and its uses
WO2019062642A1 (zh) 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
JP2018519834A (ja) ヒトＦｃ受容体に結合する融合タンパク質
CN114901310A (zh) 使用il-2受体激动剂和免疫检查点抑制剂的组合疗法
US20250026805A1 (en) Novel proteins
JP2025515191A (ja) 新規ｃｄ２００融合タンパク質
JP2024544972A (ja) Ｓｉｒｐ１ａ及びｃｄ４０ｌベースのキメラタンパク質
US20260116951A1 (en) Novel cd200 fusion proteins
US20260116946A1 (en) Novel cd200 fusion proteins
CN117295758A (zh) 包含抗原结合结构域及细胞因子三聚体结构域的融合蛋白
EA042608B1 (ru) Мутант cd200 и его применения
JP2025516364A (ja) 新規ｃｄ２００融合タンパク質
CN102470157A (zh) 广谱erbb配体结合分子及其制备和使用方法
US20230272026A1 (en) A fusion protein comprising an antigen binding domain and a cytokine trimer domain
WO2024231809A1 (en) Cd200 fusion proteins

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220401

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240910

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20241126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250203

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250507

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250507

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20250711

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250711

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250711

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250711

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250711

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260218